Market Overview

UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following Disappointing Phase II Results

Share:
Related RIGL
BMO Analysts Initiate Coverage On Rigel Pharma, Seeing 65% Upside
Benzinga's Top Initiations

Piper Jaffray reiterated its Overweight rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and increased its price target from $14 to $8.

Piper Jaffray commented, "We are maintaining our Overweight rating but cutting our price target to $8 from $14 following disappointing results from the OSKIRA-4 Phase II trial. In particular, fostamatinib's inability to achieve non-inferiority to Abbott's Humira could have negative commercial implications. As a result, we have reduced our fostamatinib revenue estimates."

Rigel Pharmaceuticals closed at $5.90 on Wednesday.

Latest Ratings for RIGL

DateFirmActionFromTo
Aug 2016BMO CapitalInitiates Coverage onOutperform
Jul 2016H.C. WainwrightInitiates Coverage onBuy
Jun 2016Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!